Bind Research is delighted to welcome Melissa Strange in her new role as Chief Financial Officer.

Melissa Strange is a commercially-minded senior finance leader with over 16 years worth of experience in life sciences companies. Melissa has been involved from early-stage research through clinical development and into commercial phases, and has worked across biotech, healthtech and medtech, where she has provided expertise in financial strategy, tax management and has supported a range of commercial and corporate transactions, including significant dilutive and non-dilutive funding. Prior to joining Bind Melissa served as Chief Financial Officer at Infinitopes, Brainomix and Closed Loop Medicine and was VP, Finance for Summit Therapeutics, a NASDAQ listed biotech. Melissa is also Chair of the Finance and Tax Advisory Committee at the BioIndustry Association. Melissa will be overseeing Bind’s financial operations and legal aspects.